Julie K Andersen

List of Publications by Year
in descending order

129 papers	12,737 citations	36271 51 h-index	23514 111 g-index
131 all docs	131 docs citations	131 times ranked	16033 citing authors

#	Article	IF	Citations
1	Longitudinal Functional Study of Murine Aging: A Resource for Future Study Designs. JBMR Plus, 2021, 5, e10466.	1.3	8
2	mTORC2: The other mTOR in autophagy regulation. Aging Cell, 2021, 20, e13431.	3.0	76
3	Alpha-Synuclein Preformed Fibrils Induce Cellular Senescence in Parkinsonâ€™s Disease Models. Cells, 2021, 10, 1694.	1.8	29
4	The mitochondrial permeability transition pore activates the mitochondrial unfolded protein response and promotes aging. ELife, 2021, 10, .	2.8	30
5	A guide to senolytic intervention in neurodegenerative disease. Mechanisms of Ageing and Development, 2021, 200, 111585.	2.2	13
6	Swimming exercise reduces native âº-synuclein protein species in a transgenic model of Parkinson's disease. MicroPublication Biology, 2021, 2021, .	0.1	0
7	Senescence as an Amyloid Cascade: The Amyloid Senescence Hypothesis. Frontiers in Cellular Neuroscience, 2020, 14, 129.	1.8	35
8	Dysregulated iron metabolism in C. elegans catp-6/ATP13A2 mutant impairs mitochondrial function. Neurobiology of Disease, 2020, 139, 104786.	2.1	30
9	Microdose lithium reduces cellular senescence in human astrocytes - a potential pharmacotherapy for COVID-19?. Aging, 2020, 12, 10035-10040.	1.4	16
10	Quantification of Insoluble Protein Aggregation in Caenorhabditis elegans during Aging with a Novel Data-Independent Acquisition Workflow. Journal of Visualized Experiments, 2020, , .	0.2	3
11	Targeting kinases in Parkinson's disease: A mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium. Journal of the Neurological Sciences, 2019, 402, 121-130.	0.3	20
12	Unknown fates of (brain) oxidation or UFO: Close encounters with neuronal senescence. Free Radical Biology and Medicine, 2019, 134, 695-701.	1.3	16
13	Hsp90 Co-chaperone p23 contributes to dopaminergic mitochondrial stress via stabilization of PHD2: Implications for Parkinsonâ€™s disease. NeuroToxicology, 2018, 65, 166-173.	1.4	16
14	Cellular Senescence Is Induced by the Environmental Neurotoxin Paraquat and Contributes to Neuropathology Linked to Parkinsonâ€™s Disease. Cell Reports, 2018, 22, 930-940.	2.9	342
15	An inducible MAO-B mouse model of Parkinsonâ€™s disease: a tool towards better understanding basic disease mechanisms and developing novel therapeutics. Journal of Neural Transmission, 2018, 125, 1651-1658.	1.4	23
16	Screening Method for Identifying Toxicants Capable of Inducing Astrocyte Senescence. Toxicological Sciences, 2018, 166, 16-24.	1.4	9
17	A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses Î±-syn- and MPTP-induced toxicities inÂvivo. Neuropharmacology, 2017, 123, 88-99.	2.0	31
18	Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimerâ€™s Disease. Journal of Pharmacology and Experimental Therapeutics, 2017, 362, 413-423.	1.3	72

#	Article	IF	Citations
19	Anti-Inflammatory and Neuroprotective Role of Natural Product Securinine in Activated Glial Cells: Implications for Parkinsonâ€™s Disease. Mediators of Inflammation, 2017, 2017, 1-11.	1.4	49
20	Detrimental effects of oxidative losses in parkin activity in a model of sporadic Parkinson's disease are attenuated by restoration of PGC1alpha. Neurobiology of Disease, 2016, 93, 115-120.	2.1	28
21	Regulation of ATP13A2 via PHD2-HIF1Î± Signaling Is Critical for Cellular Iron Homeostasis: Implications for Parkinson's Disease. Journal of Neuroscience, 2016, 36, 1086-1095.	1.7	50
22	Parkinsonâ€™s Disease and Aging. , 2016, , 229-255.		1
23	Antihelminthic Benzimidazoles Are Novel HIF Activators That Prevent Oxidative Neuronal Death via Binding to Tubulin. Antioxidants and Redox Signaling, 2015, 22, 121-134.	2.5	17
24	The combination of lithium and l-Dopa/Carbidopa reduces MPTP-induced abnormal involuntary movements (AIMs) via calpain-1 inhibition in a mouse model: Relevance for Parkinson×³s disease therapy. Brain Research, 2015, 1622, 127-136.	1.1	21
25	Mitochondrial Quality Control via the PGC1Î±-TFEB Signaling Pathway Is Compromised by Parkin Q311X Mutation But Independently Restored by Rapamycin. Journal of Neuroscience, 2015, 35, 12833-12844.	1.7	108
26	Cellular senescence and the aging brain. Experimental Gerontology, 2015, 68, 3-7.	1.2	218
27	Pharmacological Prolyl Hydroxylase Domain Inhibition as a Therapeutic Target for Parkinsonâ€™s Disease. CNS and Neurological Disorders - Drug Targets, 2014, 13, 120-125.	0.8	5
28	Iron promotes protein insolubility and aging in C. elegans. Aging, 2014, 6, 975-988.	1.4	57
29	Catecholamine metabolism drives generation of mitochondrial DNA deletions in dopaminergic neurons. Brain, 2014, 137, 354-365.	3.7	41
30	The highâ€affinity D2/D3 agonist D512 protects <scp>PC</scp>12 cells from 6â€<scp>OHDA</scp>â€induced apoptotic cell death and rescues dopaminergic neurons in the <scp>MPTP</scp> mouse model of Parkinson's disease. Journal of Neurochemistry, 2014, 131, 74-85.	2.1	26
31	Lithium prevents parkinsonian behavioral and striatal phenotypes in an aged parkin mutant transgenic mouse model. Brain Research, 2014, 1591, 111-117.	1.1	26
32	Manganese disturbs metal and protein homeostasis in Caenorhabditis elegans. Metallomics, 2014, 6, 1816-1823.	1.0	41
33	Reactive oxygen and nitrogen species in neurodegeneration. Free Radical Biology and Medicine, 2013, 62, 1-3.	1.3	7
34	Anti-Inflammatory Role of the Isoflavone Diadzein in Lipopolysaccharide-Stimulated Microglia: Implications for Parkinsonâ€™s Disease. Neurotoxicity Research, 2013, 23, 145-153.	1.3	64
35	Environmental stress, ageing and glial cell senescence: a novel mechanistic link to Parkinson's disease?. Journal of Internal Medicine, 2013, 273, 429-436.	2.7	131
36	Age-Related Behavioral Phenotype of an Astrocytic Monoamine Oxidase-B Transgenic Mouse Model of Parkinsonâ€™s Disease. PLoS ONE, 2013, 8, e54200.	1.1	58

#	Article	IF	Citations
37	A DNA synthesis inhibitor is protective against proteotoxic stressors via modulation of fertility pathways in Caenorhabditis elegans. Aging, 2013, 5, 759-769.	1.4	33
38	Mao-B elevation decreases parkin's ability to efficiently clear damaged mitochondria: protective effects of rapamycin. Free Radical Research, 2012, 46, 1011-1018.	1.5	37
39	Mitochondrial DNA damage Is associated with reduced mitochondrial bioenergetics in Huntington's disease. Free Radical Biology and Medicine, 2012, 53, 1478-1488.	1.3	112
40	Late-life hemoglobin and the incidence of Parkinson's disease. Neurobiology of Aging, 2012, 33, 914-920.	1.5	33
41	Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: Implications for Parkinsonâ€™s disease. Free Radical Biology and Medicine, 2012, 53, 993-1003.	1.3	152
42	A Possible Novel Anti-Inflammatory Mechanism for the Pharmacological Prolyl Hydroxylase Inhibitor 3,4-Dihydroxybenzoate: Implications for Use as a Therapeutic for Parkinsonâ€™s Disease. Parkinson's Disease, 2012, 2012, 1-12.	0.6	14
43	Inducible dopaminergic glutathione depletion in an alpha-synuclein transgenic mouse model results in age-related olfactory dysfunction. Neuroscience, 2011, 172, 379-386.	1.1	23
44	Mutant Î±â€synuclein and aging reduce neurogenesis in the acute 1â€methylâ€4â€phenylâ€1,2,3,6â€tetrahydropyridine model of Parkinsonâ€™s disease. Aging Cell, 2011, 10, 255-262.	3.0	28
45	Cellular senescence: A link between cancer and age-related degenerative disease?. Seminars in Cancer Biology, 2011, 21, 354-9.	4.3	339
46	Acute and longâ€term response of dopamine nigrostriatal synapses to a single, lowâ€dose episode of 3â€nitropropionic acidâ€mediated chemical hypoxia. Synapse, 2011, 65, 339-350.	0.6	8
47	Lithium protects against oxidative stressâ€mediated cell death in Î±â€synucleinâ€overexpressing in vitro and in vivo models of Parkinson's disease. Journal of Neuroscience Research, 2011, 89, 1666-1675.	1.3	55
48	Dopamine D₂/D₃ Agonists with Potent Iron Chelation, Antioxidant and Neuroprotective Properties: Potential Implication in Symptomatic and Neuroprotective Treatment of Parkinsonâ€™s Disease. ChemMedChem, 2011, 6, 991-995.	1.6	31
49	Ability to delay neuropathological events associated with astrocytic MAO-B increase in a Parkinsonian mouse model: Implications for early intervention on disease progression. Neurobiology of Disease, 2011, 43, 527-532.	2.1	16
50	Prospects and challenges for the use of stem cell technologies to develop novel therapies for Parkinson disease. Cell Cycle, 2011, 10, 4179-4180.	1.3	1
51	Intrinsic Bioenergetic Properties and Stress Sensitivity of Dopaminergic Synaptosomes. Journal of Neuroscience, 2011, 31, 4524-4534.	1.7	46
52	Quantitative Mapping of Reversible Mitochondrial Complex I Cysteine Oxidation in a Parkinson Disease Mouse Model. Journal of Biological Chemistry, 2011, 286, 7601-7608.	1.6	54
53	Nitrosylation and nitration of mitochondrial complex I in Parkinson's disease. Free Radical Research, 2011, 45, 53-58.	1.5	81
54	Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration. Neurobiology of Disease, 2010, 37, 307-313.	2.1	50

#	Article	IF	Citations
55	Ability to delay neuropathological events associated with astrocytic MAO-B increase in a Parkinsonian mouse model: Implications for early intervention on disease progression. Neurobiology of Disease, 2010, 40, 444-448.	2.1	29
56	Iron elevations in the aging Parkinsonian brain: a consequence of impaired iron homeostasis?. Journal of Neurochemistry, 2010, 112, 332-339.	2.1	61
57	Synergistic effects of environmental risk factors and gene mutations in Parkinsonâ€™s disease accelerate ageâ€related neurodegeneration. Journal of Neurochemistry, 2010, 115, 1363-1373.	2.1	41
58	Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neuroscience Letters, 2010, 486, 235-239.	1.0	350
59	Arvid Carlsson: An Early Pioneer in Translational Medicine. Science Translational Medicine, 2009, 1, 2ps3.	5.8	6
60	A Disruption in Iron-Sulfur Center Biogenesis via Inhibition of Mitochondrial Dithiol Glutaredoxin 2 May Contribute to Mitochondrial and Cellular Iron Dysregulation in Mammalian Glutathione-Depleted Dopaminergic Cells: Implications for Parkinson's Disease. Antioxidants and Redox Signaling, 2009, 11, 2083-2094.	2.5	77
61	Chronic expression of H-ferritin in dopaminergic midbrain neurons results in an age-related expansion of the labile iron pool and subsequent neurodegeneration: implications for Parkinson's disease. Brain Research, 2009, 1297, 17-22.	1.1	46
62	Iron-enhanced paraquat-mediated dopaminergic cell death due to increased oxidative stress as a consequence of microglial activation. Free Radical Biology and Medicine, 2009, 46, 312-320.	1.3	63
63	Glutathione depletion in immortalized midbrain-derived dopaminergic neurons results in increases in the labile iron pool: Implications for Parkinson's disease. Free Radical Biology and Medicine, 2009, 46, 593-598.	1.3	48
64	Reactive oxygen species regulation by AIF- and complex I-depleted brain mitochondria. Free Radical Biology and Medicine, 2009, 46, 939-947.	1.3	58
65	Endoplasmic Reticulum Stressâ€“Induced Cell Death in Dopaminergic Cells: Effect of Resveratrol. Journal of Molecular Neuroscience, 2009, 39, 157-168.	1.1	24
66	Metabolic Control Analysis in a Cellular Model of Elevated MAO-B: Relevance to Parkinsonâ€™s Disease. Neurotoxicity Research, 2009, 16, 186-193.	1.3	37
67	Preferentially Increased Nitration of Î±-Synuclein at Tyrosine-39 in a Cellular Oxidative Model of Parkinsonâ€™s Disease. Analytical Chemistry, 2009, 81, 7823-7828.	3.2	103
68	Inhibition of Prolyl Hydroxylase Protects against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Neurotoxicity. Journal of Biological Chemistry, 2009, 284, 29065-29076.	1.6	86
69	Coupling Endoplasmic Reticulum Stress to the Cell Death Program in Dopaminergic Cells: Effect of Paraquat. NeuroMolecular Medicine, 2008, 10, 333-342.	1.8	49
70	Oxidative and nitrative protein modifications in Parkinson's disease. Free Radical Biology and Medicine, 2008, 44, 1787-1794.	1.3	172
71	Insights into the effects of Î±-synuclein expression and proteasome inhibition on glutathione metabolism through a dynamic in silico model of Parkinson's disease: validation by cell culture data. Free Radical Biology and Medicine, 2008, 45, 1290-1301.	1.3	17
72	MAO-B Elevation in Mouse Brain Astrocytes Results in Parkinson's Pathology. PLoS ONE, 2008, 3, e1616.	1.1	230

#	Article	IF	Citations
73	Fibroblast growth factor 2 enhances striatal and nigral neurogenesis in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Neuroscience, 2008, 153, 664-670.	1.1	63
74	Redox imbalance in Parkinson's disease. Biochimica Et Biophysica Acta - General Subjects, 2008, 1780, 1362-1367.	1.1	232
75	Do Alterations in Glutathione and Iron Levels Contribute to Pathology Associated with Parkinson's Disease?. Novartis Foundation Symposium, 2008, , 11-25.	1.2	11
76	Inducible Alterations of Glutathione Levels in Adult Dopaminergic Midbrain Neurons Result in Nigrostriatal Degeneration. Journal of Neuroscience, 2007, 27, 13997-14006.	1.7	131
77	Iron and Paraquat as Synergistic Environmental Risk Factors in Sporadic Parkinson's Disease Accelerate Age-Related Neurodegeneration. Journal of Neuroscience, 2007, 27, 6914-6922.	1.7	119
78	Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiology of Aging, 2007, 28, 907-913.	1.5	127
79	Mitochondrial Complex I Inhibition in Parkinson's Disease: How Can Curcumin Protect Mitochondria?. Antioxidants and Redox Signaling, 2007, 9, 399-408.	2.5	101
80	Chronic ferritin expression within murine dopaminergic midbrain neurons results in a progressive age-related neurodegeneration. Brain Research, 2007, 1140, 188-194.	1.1	36
81	In vitro and in vivo neuroprotection by Î³-glutamylcysteine ethyl ester against MPTP: Relevance to the role of glutathione in Parkinson's disease. Neuroscience Letters, 2006, 402, 137-141.	1.0	40
82	Up-regulation of Î³-glutamyl transpeptidase activity following glutathione depletion has a compensatory rather than an inhibitory effect on mitochondrial complex I activity: implications for Parkinson's disease. Free Radical Biology and Medicine, 2006, 40, 1557-1563.	1.3	40
83	Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: Implications for Parkinson's disease. Free Radical Biology and Medicine, 2006, 41, 1442-1448.	1.3	114
84	Role of HIF-1 in Iron Regulation: Potential Therapeutic Strategy for Neurodegenerative Disorders. Current Molecular Medicine, 2006, 6, 883-893.	0.6	46
85	Nigrostriatal Dopaminergic Neurodegeneration in the Weaver Mouse Is Mediated via Neuroinflammation and Alleviated by Minocycline Administration. Journal of Neuroscience, 2006, 26, 11644-11651.	1.7	47
86	Mitochondrial Complex I Inhibition in Parkinson's Disease: How Can Curcumin Protect Mitochondria?. Antioxidants and Redox Signaling, 2006, .	2.5	5
87	Iron Dysregulation and Neurodegeneration: The Molecular Connection. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2006, 6, 89-97.	3.4	75
88	Iron dysregulation and Parkinson's disease. Journal of Alzheimer's Disease, 2005, 6, S47-S52.	1.2	53
89	Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells is via an NO-mediated pathway not involving peroxynitrite: implications for Parkinson's disease. Journal of Neurochemistry, 2005, 92, 1091-1103.	2.1	100
90	Role of oxidative stress in paraquat-induced dopaminergic cell degeneration. Journal of Neurochemistry, 2005, 93, 1030-1037.	2.1	229

#	Article	IF	Citations
91	Rapid Purification and Mass Spectrometric Characterization of Mitochondrial NADH Dehydrogenase (Complex I) from Rodent Brain and a Dopaminergic Neuronal Cell Line. Molecular and Cellular Proteomics, 2005, 4, 84-96.	2.5	47
92	Superoxide Dismutase/Catalase Mimetics Are Neuroprotective against Selective Paraquat-mediated Dopaminergic Neuron Death in the Substantial Nigra. Journal of Biological Chemistry, 2005, 280, 29194-29198.	1.6	146
93	Dopaminergic neurons. International Journal of Biochemistry and Cell Biology, 2005, 37, 942-946.	1.2	256
94	The Herbicide Paraquat Induces Dopaminergic Nigral Apoptosis through Sustained Activation of the JNK Pathway. Journal of Biological Chemistry, 2004, 279, 32626-32632.	1.6	203
95	Oxidative stress in neurodegeneration: cause or consequence?. Nature Medicine, 2004, 10, S18-S25.	15.2	1,562
96	Perspectives on MAO-B in Aging and Neurological Disease: Where Do We Go From Here?. Molecular Neurobiology, 2004, 30, 077-090.	1.9	70
97	Does cellular iron dysregulation play a causative role in Parkinsonâ€™s disease?. Ageing Research Reviews, 2004, 3, 327-343.	5.0	110
98	Paraquat and iron exposure as possible synergistic environmental risk factors in Parkinsonâ€™s disease. Neurotoxicity Research, 2003, 5, 307-313.	1.3	37
99	The Role of c-Jun N-Terminal Kinase (JNK) in Parkinson's Disease. IUBMB Life, 2003, 55, 267-271.	1.5	82
100	Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo. Neuron, 2003, 37, 899-909.	3.8	594
101	Oxidative Î±-Ketoglutarate Dehydrogenase Inhibition via Subtle Elevations in Monoamine Oxidase B Levels Results in Loss of Spare Respiratory Capacity. Journal of Biological Chemistry, 2003, 278, 46432-46439.	1.6	110
102	Defects in Dynein Linked to Motor Neuron Degeneration in Mice. Science of Aging Knowledge Environment: SAGE KE, 2003, 2003, 10pe-10.	0.9	2
103	Inhibition of Caspases Protects Cerebellar Granule Cells of the Weaver Mouse from Apoptosis and Improves Behavioral Phenotype. Journal of Biological Chemistry, 2002, 277, 44285-44291.	1.6	28
104	Glutathione, iron and Parkinsonâ€™s disease. Biochemical Pharmacology, 2002, 64, 1037-1048.	2.0	372
105	Glutathione decreases in dopaminergic PC12 cells interfere with the ubiquitin protein degradation pathway: relevance for Parkinson's disease?. Journal of Neurochemistry, 2002, 80, 555-561.	2.1	66
106	Ironing out Parkinson's disease: is therapeutic treatment with iron chelators a real possibility?. Aging Cell, 2002, 1, 17-21.	3.0	43
107	Time to Talk SENS: Critiquing the Immutability of Human Aging. Annals of the New York Academy of Sciences, 2002, 959, 452-462.	1.8	152
108	Caspase-9 Activation Results in Downstream Caspase-8 Activation and Bid Cleavage in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinson's Disease. Journal of Neuroscience, 2001, 21, 9519-9528.	1.7	282

#	Article	IF	Citations
109	Caspase 3 inhibition attenuates hydrogen peroxide-induced DNA fragmentation but not cell death in neuronal PC12 cells. Journal of Neurochemistry, 2001, 76, 1745-1755.	2.1	39
110	Glutamyl cysteine synthetase catalytic and regulatory subunits localize to dopaminergic nigral neurons as well as to astrocytes. Journal of Neuroscience Research, 2001, 64, 203-206.	1.3	6
111	Does neuronal loss in Parkinson's disease involve programmed cell death?. BioEssays, 2001, 23, 640-646.	1.2	68
112	Genetically Engineered Mice and Their Use in Aging Research. Molecular Biotechnology, 2001, 19, 045-058.	1.3	6
113	Alpha synuclein aggregation: is it the toxic gain of function responsible for neurodegeneration in Parkinson's disease?. Mechanisms of Ageing and Development, 2001, 122, 1499-1510.	2.2	57
114	The Hunt for a Cure for Parkinson's Disease. Science of Aging Knowledge Environment: SAGE KE, 2001, 2001, 1re-1.	0.9	2
115	The real Dorian Gray mouse. BioEssays, 2000, 22, 410-413.	1.2	20
116	What causes the build-up of ubiquitin-containing inclusions in Parkinsonâ€™s disease?. Mechanisms of Ageing and Development, 2000, 118, 15-22.	2.2	31
117	Mice Deficient in Cellular Glutathione Peroxidase Show Increased Vulnerability to Malonate, 3-Nitropropionic Acid, and 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine. Journal of Neuroscience, 2000, 20, 1-7.	1.7	2,029
118	The Role of Iron in Parkinson Disease and 1â€Methylâ€4â€Phenylâ€1,2,3,6â€Tetrahydropyridine Toxicity. IUBMB Life, 1999, 48, 139-141.	1.5	22
119	Brain Î³-glutamyl cysteine synthetase (GCS) mRNA expression patterns correlate with regional-specific enzyme activities and glutathione levels. Journal of Neuroscience Research, 1999, 58, 436-441.	1.3	56
120	Brain Î³â€glutamyl cysteine synthetase (GCS) mRNA expression patterns correlate with regionalâ€specific enzyme activities and glutathione levels. Journal of Neuroscience Research, 1999, 58, 436-441.	1.3	2
121	Stress, Aging, and Neurodegenerative Disorders: Molecular Mechanismsa. Annals of the New York Academy of Sciences, 1998, 851, 429-443.	1.8	47
122	Use of genetically engineered mice as models for exploring the role of oxidative stress in neurodegenerative diseases. Frontiers in Bioscience - Landmark, 1998, 3, c8-16.	3.0	4
123	Cloning/brain localization of mouse glutamylcysteine synthetase heavy chain mRNA. NeuroReport, 1997, 8, 2053-2060.	0.6	20
124	Elevated expression of glutathione peroxidase in PC12 cells results in protection against methamphetamine but not MPTP toxicity. Molecular Brain Research, 1997, 46, 154-160.	2.5	37
125	Decreased Glutathione Results in Calcium-Mediated Cell Death in PC12. Free Radical Biology and Medicine, 1997, 23, 1055-1066.	1.3	63
126	Increased expression of monoamine oxidase-B results in enhanced neurite degeneration in methamphetamine-treated PC12 cells. Journal of Neuroscience Research, 1997, 50, 618-626.	1.3	22

#	Article	IF	Citations
127	Use of Genetically Engineered Mice As Models for Understanding Human Neurodegenerative Disease. Journal of the American Geriatrics Society, 1996, 44, 717-722.	1.3	4
128	Herpesvirus-mediated gene delivery into the rat brain: specificity and efficiency of the neuron-specific enolase promoter. Cellular and Molecular Neurobiology, 1993, 13, 503-515.	1.7	128
129	1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Resistant, Flat-Cell PC12 Variants Having a Partial Loss of Transformed Phenotype. Journal of Neurochemistry, 1990, 55, 559-567.	2.1	16